Novome Biotechnologies is a biotechnology company focused on engineering defined activities into the human gut microbiota to treat a wide range of diseases. The Company has developed the first platform for controlled colonization of the gut with engineered bacteria, enabling first-in-class living therapeutics known as Genetically Engineered Microbial Medicines (GEMMs). The Company’s lead program in hyperoxaluria will enter the clinic in Q2 2021 and is focused on the development of a live biotherapeutic product that degrades oxalate to prevent the formation of kidney stones. Additional programs are being pursued in a range of diseases, including IBD, IBS and I/O, that leverage the Company’s proprietary synthetic biology platform and expertise in the gut microbiome. Novome is backed by leading investors, including 5AM Ventures, Alta Partners and DCVC Bio.
Privately Funded Company
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):